Evidence map›Paper›PMID 42524851›Full record

ArticleInternal medicine journal2026

Regulatory standardisation to improve the safety of continuous glucose monitoring systems in Australia and New Zealand: joint ADS/ADEA/ADIPS/ANZSPED/NZSSD statement.

Sofianos Andrikopoulos, Lisa M Raven, Ramzi Ajjan, Kate Lomax, Tara Whelan, Brett Fenton, Amanda Bartlett, Shantha Joseph, Matthew Hare, Mary B Abraham and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sofianos AndrikopoulosAustralian Diabetes Society, Sydney, New South Wales, Australia.
Lisa M RavenDepartment of Endocrinology and Diabetes, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
Ramzi AjjanLeeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
Kate LomaxDepartment of Endocrinology and Diabetes, Perth Children's Hospital, Perth, Western Australia, Australia.
Tara WhelanAustralian Diabetes Educators Association, Canberra, Australian Capital Territory, Australia.
Brett FentonAustralian Diabetes Educators Association, Canberra, Australian Capital Territory, Australia.
Amanda BartlettAustralian Diabetes Educators Association, Canberra, Australian Capital Territory, Australia.
Shantha JosephSouthern Adelaide Diabetes and Endocrine Services, Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, South Australia, Australia.
Matthew HareMenzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Mary B AbrahamDepartment of Endocrinology and Diabetes, Perth Children's Hospital, Perth, Western Australia, Australia.ORCID https://orcid.org/0000-0002-3628-1735
Hamish R CrocketSchool of Health Equity and Innovation, Division of Health, University of Waikato, Hamilton, New Zealand.ORCID https://orcid.org/0000-0002-7134-6776
Tom M WilkinsonDepartment of Medicine, University of Otago Christchurch, Christchurch, New Zealand.ORCID https://orcid.org/0000-0002-9025-3778
Joanna McClintockNew Zealand Society for the Study of Diabetes, New Zealand.
Benjamin J WheelerDepartment of Paediatrics and Child Health, University of Otago, Dunedin, New Zealand.ORCID https://orcid.org/0000-0003-3348-5238
Glynis P RossDepartment of Endocrinology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Self-monitoring of glycaemia is a cornerstone of diabetes management, particularly for people using insulin. Traditionally, glucose monitoring involved finger-pricking and measuring capillary blood glucose concentration. Continuous glucose monitors (CGMs) have revolutionised self-monitoring of glucose levels. These devices provide continuous interstitial fluid glucose measurements, including trend arrows and alarms to alert the person if glucose levels are outside predetermined ranges. The increased reliance on CGM metrics for clinical decisions to manage diabetes necessitates the consideration and implementation of minimum standards that device manufacturers should meet to demonstrate safety, precision and accuracy. This statement provides recommendations to ensure that CGM devices that are approved for the Australian and New Zealand markets meet/exceed these minimum standards of accuracy, to provide health professionals and people living with diabetes the confidence to manage their glucose levels effectively.

Indexed as

Blood GlucoseBlood Glucose Self-MonitoringContinuous Glucose MonitoringAustraliaHumansNew ZealandBlood GlucoseCGMcontinuous glucose monitordiabetestype 1 diabetes

Identifiers

PMID42524851
PMCPMC13547907

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.